1. Home
  2. BTX vs IRWD Comparison

BTX vs IRWD Comparison

Compare BTX & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Technology and Private Equity Term Trust

BTX

BlackRock Technology and Private Equity Term Trust

HOLD

Current Price

$6.64

Market Cap

780.8M

Sector

N/A

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.29

Market Cap

741.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTX
IRWD
Founded
N/A
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
780.8M
741.8M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
BTX
IRWD
Price
$6.64
$3.29
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$4.94
AVG Volume (30 Days)
653.6K
3.1M
Earning Date
11-01-2025
05-06-2026
Dividend Yield
12.53%
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.15
Revenue
N/A
$298,276,000.00
Revenue This Year
N/A
$57.95
Revenue Next Year
N/A
$4.39
P/E Ratio
N/A
$20.30
Revenue Growth
N/A
8.88
52 Week Low
$5.10
$0.55
52 Week High
$7.50
$5.78

Technical Indicators

Market Signals
Indicator
BTX
IRWD
Relative Strength Index (RSI) 52.88 40.97
Support Level $6.55 $3.08
Resistance Level $6.92 $3.53
Average True Range (ATR) 0.17 0.23
MACD 0.01 -0.01
Stochastic Oscillator 72.03 32.02

Price Performance

Historical Comparison
BTX
IRWD

About BTX BlackRock Technology and Private Equity Term Trust

BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Share on Social Networks: